Actuate Therapeutics Inc
NASDAQ:ACTUBiotechnology
+$0.06 today
- Market cap
- $50.01M
- Beta
- 0.53
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.92
Volume 0.03M
Average 0.16M
ACTU Total Liabilities
Everything the company owes to creditors and other parties.
Actuate Therapeutics IncNASDAQ: ACTU
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities falls 46.4% from a year ago
Total liabilities stood at $5.13M at the end of Q1 FY2026, down 46.4% from a year earlier and down 16.1% from the prior quarter. Over 3 fiscal years it compounded at +2.6% a year.
Context
- Total liabilities amounted to 57.5% of total assets at the end of Q1 FY2026, down 156.0 pp from a year earlier.
- Total liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -46.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 6.11M USD
- Year-over-year change
- -33.7%
- 3-year CAGR
- +2.6%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.11M | -33.7% |
| FY2024 | 2024-12-31 | 9.21M | -91.0% |
| FY2023 | 2023-12-31 | 102.62M | +1716.1% |
| FY2022 | 2022-12-31 | 5.65M | — |
Total Liabilities vs competitors
How ACTU compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -46.4% is the 8th highest of 9, against a peer median of -13.0%.
- Total liabilities amounts to 57.5% of total assets for ACTU, versus a peer median of 50.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $657.17M USD | +1419.7% | +134.5% | 129.7% | |
| Mar 2026 | $229.53M USD | -26.8% | -22.9% | 95.7% | |
| Mar 2026 | $91.12M USD | -19.9% | -34.7% | 77.5% | |
| Mar 2026 | $86.21M USD | -6.1% | -3.0% | 23.2% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $24.13M USD | +25.4% | +20.8% | 106.3% |
| Mar 2026 | $22.32M USD | -37.3% | -11.2% | 14.3% | |
| Mar 2026 | CHF 19.15M CHF | +48.4% | -7.0% | 21.9% | |
| Mar 2026 | $6.09M USD | -86.1% | -41.3% | 10.3% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $5.13M USD | -46.4% | +2.6% | 57.5% |
| Peer median (excluding ACTU) | — | -13.0% | -9.1% | 50.3% | |
Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Actuate Therapeutics Inc
NASDAQ:ACTU
Intrinsic Alpha fair value
Locked
Current Price
$2.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.